Evolution of Early-Phase Anticancer Drug Investigations in China-Reference-Cited by-全球学者库

Evolution of Early-Phase Anticancer Drug Investigations in China

Published:2022-11-01 Issue:11 Volume:8 Page:1692
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Wang Shuhang¹,Yu Yue¹,Jiang Yale¹,Zhang Huishan²,Ma Peiwen¹,Liu Gang³,Li Ning¹

Affiliation:

1. Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2. Phase I Clinical Trial Ward, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Province, China

3. Key Laboratory of Molecular Epigenetics of the Ministry of Education, Northeast Normal University, Changchun, China

Abstract

This study examines phase 1 anticancer drug clinical trials performed in China from 2017 to 2021.

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2796100/jamaoncology_wang_2022_ld_220024_1668658025.97094.pdf

Reference6 articles.

1. Anticancer drug R&D landscape in China.;Zhao;J Hematol Oncol,2020

2. Clinical trials and drug approvals continue to accelerate in China.;Wang;Lancet Oncol,2017

3. Center for Drug Evaluation and National Medical Products Administration. Announcement of Center for Drug Evaluation on issuing guidance for clinical-value-oriented research and development of anticancer drugs (No. 46 of 2021). Accessed February 21, 2022. https://www.cde.org.cn/main/news/viewInfoCommon/ef7bfde96c769308ad080bb7ab2f538e

4. National Development and Reform Commission. Guidance catalogue for key products and service of strategic emerging industry (No. 1 of 2017). Accessed February 24, 2022. https://www.ndrc.gov.cn/xxgk/zcfb/gg/201702/t20170204_961174.html?code=&state=123

5. National Intellectual Property Administration. Catalogue for key supportive industries of intellectual property (year of 2018). Accessed February 24, 2022. https://www.cnipa.gov.cn/art/2018/1/30/art_418_44867.html

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of clinical trial designs for novel anticancer drugs in China: A cohort study of drugs approved between 2015 and 2021;Drug Discovery Today;2023-06

2. Targeted protein degrader development for cancer: advances, challenges, and opportunities;Trends in Pharmacological Sciences;2023-05